Summary

  • No customer supplied more than 10% of Nexteq’s H1 2026 revenue, but the cleaner concentration statistic coincided with a 53% fall in Quixant revenue and the loss of substantial major-customer volume.
  • Nexteq moved from $25.0 million of net cash at December 2025 to $1.436 million of net debt at June 2026. Operating weakness, inventory, $8.5 million of shareholder returns and a $12 million Taiwan mortgage belong to separate ledgers; the expected sale-related reversal was still conditional.

The most revealing number in Nexteq’s interim accounts is zero. In the first half of 2026, no individual customer produced more than 10% of group revenue. A year earlier, three customers above that threshold contributed $16.8 million between them.

Read alone, the disclosure looks like diversification. Read with the income statement, it looks different. Group revenue fell 34% to $26.678 million. Quixant, the gaming-platform business, fell 53% to $12.740 million from $26.883 million. Its segment result almost disappeared, falling to $3,000 from $4.803 million. A large customer can fall below a reporting threshold because a supplier has found more demand elsewhere. It can also fall below it because that customer’s volume has gone away. Nexteq’s first half contains much more evidence for the second mechanism than for the first.

Management attributed Quixant’s decline to volume reductions at major gaming customers and the loss of Everi after its acquisition by Apollo Funds. It also said customer retention excluding Everi remained 100%. That claim preserves an important distinction: a retained relationship is not retained economics. Quixant board volumes fell 56%, from 21,900 to 9,700 units. North American revenue fell to $14.552 million from $27.411 million, while US revenue nearly halved to $13.926 million. Customers may still be present while ordering far less.

Densitron supplied real portfolio support, but not full substitution. Revenue edged up 1% to $13.938 million and its segment result improved to $2.136 million from $1.896 million. That resilience meant the display and human-machine-interface business became slightly larger than Quixant by revenue. Yet the $116,000 Densitron revenue increase did not replace Quixant’s $14.143 million decline. Combined segment results of $2.139 million also had to carry $6.902 million of corporate costs. The resulting statutory operating loss was $4.763 million.

The measurement boundary matters again below operating profit. Nexteq reported adjusted EBITDA of negative $2.823 million and an adjusted loss before tax of $3.979 million. The statutory loss before tax was larger, at $4.666 million. Adjusted measures remove share-based pay and restructuring costs, among other items; they do not turn the period profitable. The company also reported a 9% adjusted operating cash-conversion rate. That positive-looking percentage comes from dividing negative adjusted operating cash flow of $362,000 by a negative adjusted loss-before-tax denominator.

It is arithmetically positive and economically awkward—not evidence of healthy conversion.

Cash therefore needs four ledgers. First, operating activity used $773,000 of cash, against an inflow a year earlier. Second, inventories rose to $23.972 million from $16.456 million at December, with a $7.695 million inventory increase in the cash-flow statement. Management describes some of this as strategic purchasing of critical components to secure cost and lead times. Third, Nexteq returned about $8.5 million to shareholders through $5.672 million of buy-backs and $2.835 million of dividends. Fourth, it drew $11.969 million of loans, principally the short-term mortgage tied to the new Taiwan office.

Those flows moved the group from $25.0 million of net cash at December 2025 to $1.436 million of net debt at June 2026. Property, plant and equipment rose to $19.855 million from $4.643 million over the same dates. The mortgage makes the closing balance look worse than the operating ledger alone; it does not erase the adjusted loss, inventory build or cash returned to shareholders.

After the balance-sheet date, Nexteq’s Taiwan branch accepted an offer to sell the new Taipei office. The qualifications are as important as the headline. The offer was non-binding. The $1.5 million guarantee deposit was returnable. Completion was expected in October 2026. Management expected the transaction to increase cash by more than $3 million and net cash by more than $15 million, but those were prospective effects, not cash recovered by 30 June.

The outlook carries the same conditional structure. Nexteq cited 83% order coverage at the end of August, short-lead Densitron demand, Quixant stock on hand and two significant gaming orders still needed to secure the year-end position. It also identified $1.3 million of annual overhead savings from H1 actions. Annualised savings are not the same as first-half benefit, and order coverage is not recognised revenue.

The evidence is unusually explicit about its limits. The interim information is unaudited and was neither audited nor reviewed; the directors did not adopt IAS 34. Investors therefore have a useful operating map, but not a completed audit trail. Genuine diversification will show up when new customers and products replace lost volume, segment contribution covers the corporate cost base and operating cash improves without depending on an asset sale. A cleaner 10% table cannot do that work by itself.

Sources